However, the development of a new class of drugs, the so-called CFTR modulators, has set a new milestone in the treatment of cystic fibrosis since Ivacaftor, a CFTR potentiator, proved to be very efficacious in patients carrying a G551D gating mutation and was subsequently introduced in 2012 [8]. Here, CFTR is linked to cystic fibrosis.